Volcano (NSDQ:VOLC) agreed to give Crux Biomedical an extra 5 months to obtain FDA 510(k) clearance for a retrieval device, a milestone worth $3 million under the terms their merger agreement.
Crux Biomedical
CareFusion updates on annual report | Wall Street Beat
CareFusion (NYSE:CFN) said it’s done with most of its review of the accounting for its Pyxis medication dispensing line, which delayed the filing of its 4th-quarter and annual reports and prompted a warning from the New York Stock Exchange.
Volcano has big plans for new $36M Crux Biomedical acquisition
Breast cancer: Ultrasound-guided surgery bests “blind” tumor removal | MassDevice.com On Call
MASSDEVICE ON CALL — Ultrasound-guided breast tumor removal proved "much more successful" than standard surgery in excising all cancerous tissue while leaving as much healthy tissue as possible, according to a report unveiled at the European Breast Cancer Conference last week.
Researchers expect their findings to reform the standard of care for palpable breast tumors, or those that can be felt, according to a press release.
Medtronic enrolls first patient in Fire & Ice ablation study | Regulatory Roundup
Medtronic’s Arctic Front cryoablation system
Medtronic (NYSE:MDT) enrolled the first of up to 572 patients in its Fire & Ice trial, the largest clinical study to date to compare 2 atrial fibrillation ablation systems.
Medtronic wins 510(k) for surgical sealer | Regulatory Roundup
Medtronic (NYSE:MDT) won 510(k) clearance from the FDA for the Aquamantys surgical sealer it acquired when it paid $480 million for Salient Surgical Technologies last year.
Access Scientific scoops up $10 million | Funding Roundup
Access Scientific Inc., makers of the Picc Wand and Power Wand IV catheters, closed a $10 million equity financing round.
Investment was led by CAC, a private equity firm, and followed by Access Scientific’s previous investors.
The company’s IV catheters are designed reduce patient discomfort by allowing blood tests to be drawn and fluids and medications to be delivered through a single device, which can last the duration of an entire hospital stay.
Johnson & Johnson names new DePuy Spine president
Namal Nawana is the new president of DePuy Spine, succeeding Gary Fischetti, who was named chairman of the DePuy group in January by its corporate parent, Johnson & Johnson (NYSE:JNJ).
Nawana, a 13-year vet at the New Brunswick, N.J.-based medical products conglomerate, pulled stints in several areas, including engineering, marketing, sales and general management in Europe, Canada, Australia and the Asia Pacific, according to a press release.
